NaturePulse

SciencePulse · Biology

Casgevy: The First CRISPR Gene-Editing Therapy Approved

In late 2023, regulators in the UK and US approved Casgevy — the first medicine based on CRISPR gene editing — to treat sickle-cell disease by editing a patient's own blood stem cells.

The world's first approved CRISPR medicine, which edits a patient's cells to treat sickle-cell disease and beta-thalassemia.

For the curious

Scientists found a way to fix a tiny spelling mistake in a person's DNA — like using a find-and-replace tool in a story about you! A medicine called Casgevy fixes blood cells so they can carry oxygen properly again.

For students

CRISPR is a molecular scissor borrowed from bacteria. Casgevy edits blood stem cells outside the body: it switches the fetal haemoglobin gene back on, compensating for the faulty adult gene behind sickle-cell disease. In trials, most treated patients were freed from the disease's severe pain crises for over a year and counting.

Going deeper

The therapy disrupts the BCL11A enhancer in hematopoietic stem cells, re-expressing fetal haemoglobin. Autologous ex-vivo editing avoids immune rejection but requires chemotherapy conditioning and costs around $2 million per patient — raising hard access questions, especially for Africa, where sickle-cell disease is most common.

For experts

Casgevy validated a platform: in-vivo CRISPR (directly editing inside the body) trials now target the liver, eye and heart, while base and prime editing refine precision. Ethical consensus draws a firm line at heritable embryo editing, reaffirmed after the 2018 He Jiankui scandal. Delivery — getting editors to the right tissue — is the field's main bottleneck.

Common misconceptions

  • Casgevy does not edit future children — it edits only the patient's own blood cells, and those changes die with them.

Sources

← Research & learning